Reaction

Anal Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,765 reports · 64 co-occurring drugs

As of the last recalculation, Anal Haemorrhage appears in 2,765 FAERS reports alongside 64 co-occurring drug terms. The strongest observed disproportionality signal is ORLISTAT (PRR 27.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Orlistat	93	27.9	28.0
Dimenhydrinate	22	15.7	15.7
Vedolizumab	154	14.2	14.2
Mesalamine	94	13.0	13.0
Peginterferon Alfa-2A	83	11.9	11.9
Loperamide Hydrochloride Oral	15	11.1	11.1
Ribavirin	92	11.1	11.1
Diltiazem Hydrochloride Extended-Release Tablets	16	10.6	10.7
Terbinafine Hydrochloride	12	10.2	10.2
Loperamide Hcl	15	8.8	8.8
Infliximab-Dyyb	33	8.6	8.6
Sunitinib Malate	41	8.0	8.0
Gemfibrozil	15	7.5	7.5
Ado-Trastuzumab Emtansine	8	7.2	7.2
Clindamycin	24	6.4	6.4
Clindamycin Phosphate	27	6.1	6.1
Psyllium Husk	8	6.1	6.1
Insulin Glulisine	8	5.9	5.9
Sucralfate Oral	11	5.8	5.8
Sucralfate Oral Suspension	11	5.8	5.8
Granisetron Hydrochloride	8	5.8	5.8
Nebivolol	12	5.7	5.7
Tamsulosin Hydrochloride	15	5.6	5.6
Instalax Polyethylene Glycol 3350	9	5.5	5.5
Polyethylene Glycol 400	9	5.4	5.4
Dabigatran Etexilate Mesylate	50	5.3	5.3
Dabigatran Etexilate	53	5.2	5.2
Leucovorin Calcium	13	5.1	5.1
Isosorbide Mononitrate	14	5.1	5.1
Tizanidine	15	4.8	4.8
Mycophenilic Acid	13	4.7	4.7
Tramadol Hydrochloride	23	4.6	4.6
Fluorouracil Cream, 0.5%	46	4.6	4.6
Regorafenib	7	4.5	4.5
Fluorouracil	46	4.5	4.5
Teduglutide	8	4.5	4.5
Pegaspargase	7	4.3	4.3
Pazopanib Hydrochloride	15	4.2	4.2
Nintedanib	17	4.1	4.1
Ribociclib	17	4.1	4.1
Rivaroxaban	109	4.1	4.1
Bevacizumab	64	4.0	4.0
Pertuzumab	14	3.9	3.9
Panitumumab	8	3.9	3.9
Encorafenib	5	3.8	3.8
Fondaparinux Sodium	4	3.7	3.7
Deferasirox	13	3.7	3.7
Sorafenib	10	3.6	3.6
Ranolazine	5	3.6	3.6
Granisetron	5	3.6	3.6
Obinutuzumab	7	3.2	3.2
Fam-Trastuzumab Deruxtecan-Nxki	4	3.0	3.0
Azacitidine	11	2.8	2.8
Fesoterodine Fumarate	4	2.8	2.8
Riociguat	12	2.8	2.8
Nirmatrelvir And Ritonavir	19	2.7	2.7
Tolvaptan	5	2.6	2.6
Vemurafenib	4	2.5	2.5
Cetuximab	10	2.4	2.4
Atezolizumab	12	2.3	2.3
Sofosbuvir	6	2.3	2.3
Paricalcitol	4	2.1	2.1
Abemaciclib	5	1.9	1.9
Adapalene	3	0.1	0.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.